# Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

> **NCT03977155** · PHASE2 · COMPLETED · sponsor: **Boston Pharmaceuticals** · enrollment: 133 (actual)

## Conditions studied

- Diarrhea-predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** BOS-589
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03977155
- **Lead sponsor:** Boston Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-04
- **Primary completion:** 2020-05-06
- **Final completion:** 2020-05-06
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03977155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03977155, "Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03977155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*